WuXi Biologics announced the launch of WuXiHigh²2.0, a breakthrough formulation development platform that achieves protein concentrations up to 230 mg/mL while reducing viscosity by up to 90%. The platform surpasses the current industry benchmark, as the highest formulation concentration documented in FDA-approved biologics is 200 mg/mL.
Platform Capabilities and Technical Specifications
The WuXiHigh²2.0 technology platform leverages proprietary excipient blends and expertise to enable unprecedented concentration levels. By deploying over 24 proprietary excipient combinations, the platform substantially reduces viscosity while maintaining formulation stability and injectability.
The platform integrates high-throughput instruments to predict viscosity and aggregation risks, enabling a rapid, data-driven approach for smarter excipient selection from the earliest formulation stages. This methodology accelerates development timelines and minimizes material consumption.
Technical specifications include support for ultrafiltration/diafiltration (UF/DF) operations at viscosities up to 100 cP and precision filling at up to 50 cP, ensuring seamless technology transfer and scale-up from early clinical development to commercial manufacturing.
Market Context and Clinical Significance
High-concentration biologics, typically defined as formulations exceeding 100 mg/mL protein, have emerged as a critical R&D priority for pharmaceutical companies. Currently, over 20% of monoclonal antibody products approved by the U.S. Food and Drug Administration are high-concentration formulations.
These formulations offer significant advantages including reduced injection volume, improved dosing efficiency, and enhanced patient adherence. The enhanced concentration translates to greater flexibility in injection volume, reduced dosing frequency, and simplified cold-chain logistics, while boosting drug substance manufacturing and drug product manufacturing efficiency.
Addressing Manufacturing Challenges
The development and manufacturing of high-concentration formulations traditionally suffer from high viscosity and aggregation, which can complicate manufacturing, compromise product stability, and increase risks of immunogenicity. The WuXiHigh²2.0 platform directly addresses these challenges through its proprietary approach.
Dr. Chris Chen, CEO of WuXi Biologics, stated, "WuXiHigh²2.0 represents a transformative technology platform for next-generation biologics with high-concentration formulations. Its ability to enhance concentration while reducing viscosity redefines industry benchmarks, and more importantly elevates patient experience without compromising drug efficacy."
Company Portfolio and Global Reach
WuXi Biologics operates as a leading global Contract Research, Development and Manufacturing Organization (CRDMO) with over 12,000 skilled employees across China, the United States, Ireland, Germany, and Singapore. As of December 31, 2024, the company supports 817 integrated client projects, including 21 in commercial manufacturing, excluding COVID CMO projects.
The launch of WuXiHigh²2.0 reinforces the company's commitment to integrating innovative science with deep expertise in drug product formulation, enabling clients to efficiently accelerate development and deliver therapies to patients worldwide.
